Detection of interval distant metastases: Clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy

Cancer

Volumn 109, Issue 1, 2007, Pages 125-134

  Bruzzi, John F ^a   Swisher, Stephen G ^a   Truong, Mylene T ^a   Munden, Reginald F ^a   Hofstetter, Wayne L ^a   Macapinlac, Homer A ^a   Correa, Arlene M ^a   Mawlawi, Osama ^a   Ajani, Jaffer A ^a   Komaki, Ritsoko R ^a   Fukami, Norio ^a   Erasmus, Jeremy J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CT PET; Esophageal cancer; Neoadjuvant therapy; Staging

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIAGNOSTIC VALUE; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MUSCLE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33846363315     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22397     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462-467.
3. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727-1733.
4. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167.
5. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313.
6. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979-1984.
7. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg. 1997;114:210-217.
8. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg. 1988;96:242-248.
9. Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993;11:1118-1123.
10. Donington JS, Miller DL, Allen MS, Deschamps C, Nichols FC 3rd, Pairolero PC. Tumor response to induction chemoradiation: influence on survival after esophagectomy. Eur J Cardiothorac Surg. 2003;24:631-636; discussion 36-37.
11. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165-2174.
12. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78:1152-1160; discussion 52-60.
13. Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;101:1776-1785.
14. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-908.
15. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13:361-368.
16. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065.
17. Kato H, Kuwano H, Nakajima M, et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg. 2002;184:279-283.
18. Kroep JR, Van Groeningen CJ, Cuesta MA, et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol. 2003;5:337-346.
19. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001;233:300-309.
20. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428-432.
21. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg. 2005;129:1232-1241.
22. Wieder HA, Beer AJ, Lordick F, et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med. 2005;46:2029-2034.
23. Brink I, Hentschel M, Bley TA, et al. Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol. 2004;30:544-550.
24. Erasmus J, Munden R, Truong MT, et al. Pre-operative chemoradiation- induced ulceration in patients with esophageal cancer, a confounding factor in tumor response assessment in integrated CT-PET imaging. J Thorac Oncol. 2006;1:478-486.
25. Swisher SG, Ajani JA, Komaki R, et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003;57:120-127.
26. Bruzzi J, Swisher S, Truong M, Sabloff B, Munden R, Erasmus J. Pattern of distant organ metastases detected by integrated PET/CT imaging. Curr Prob Diagn Radiol. In press.
27. Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systematic review. Radiology. 2005;236:841-851.
28. Pan T, Mawlawi O, Nehmeh SA, et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med. 2005;46:1481-1487.
29. Nehmeh SA, Erdi YE, Pan T, et al. Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys. 2004;31:1333-1338.
30. Esophagus. American Joint Committee on Cancer: AJCC Staging Manual, 5th ed. Philadelphia: Lippincott-Raven; 1997:65-69.